secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-037608
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences reports Q4 net loss of $59.5M; outlines Phase 3 plans for tarcocimab and KSI-501
--------------------------------------------------------------------------------

- Q4 2023 net loss $59.5M ($1.13/share) vs $70.4M ($1.35/share) in Q4 2022; R&D expenses fell to $46.6M.
- Cash and equivalents $285.5M; company believes sufficient to fund operations into 2026.
- Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively enrolling; uses go-to-market formulation.
- Phase 3 DAYBREAK study in wet AMD (KSI-501 vs tarcocimab vs aflibercept) targeted to start mid-2024 after FDA discussions.
- Phase 1b study of KSI-101 planned for Q2 2024; dual pivotal studies targeted for later 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024037608/0000950170-24-037608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024037608/kod-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer